Cognitive Remediation in Schizophrenia

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.9758/cpn.2012.10.3.125</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:11179842">http://nrs.harvard.edu/urn-3:HUL.InstRepos:11179842</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Cognitive Remediation in Schizophrenia

Yoshio Kaneko1,2,3, Matcheri Keshavan1,3

Department of Psychiatry, 1Beth Israel Deaconess Medical Center, 2Brigham and Women’s Hospital, 3Harvard Medical School, Boston, MA, USA

Cognitive deficits in schizophrenia are pervasive, severe, and largely independent of the positive and negative symptoms of the illness. These deficits are increasingly considered to be core features of schizophrenia with evidence that the extent of cognitive impairment is the most salient predictor of daily functioning. Unfortunately, current schizophrenia treatment has been limited in addressing the cognitive deficits of the illness. Alterations in neuroplasticity are hypothesized to underpin these cognitive deficits, though preserved neuroplasticity may offer an avenue towards cognitive remediation. Key neuroplastic principles to consider in designing remediation interventions include ensuring sufficient intensity and duration of remediation programs, "bottom-up" training that proceeds from simple to complex cognitive processes, and individual tailoring of remediation regimens. We discuss several cognitive remediation programs, including cognitive enhancement therapy, which embrace these principles to target neurocognitive and social cognitive improvements and which have been demonstrated to be effective in schizophrenia. Future directions in cognitive remediation research include potential synergy with pharmacologic treatment, non-invasive stimulation techniques, and psychosocial interventions, identification of patient characteristics that predict outcome with cognitive remediation, and increasing the access to these interventions in front-line settings.

KEY WORDS: Schizophrenia; Cognition disorders/pathology; Cognition disorders/therapy; Cognition disorders/rehabilitation; Neuronal plasticity.
schizophrenia patients demonstrate a pattern of cognitive deficits that is similar to that of the patients themselves, it is unlikely that the patients’ cognitive impairments are simply secondary to schizophrenia symptoms or treatment.14,15

Finally, the nature of cognitive deficits in schizophrenia is distinct from the impairments observed in other neuropsychiatric and neurodevelopmental disorders. The cognitive domains most impacted in schizophrenia include memory, attention, reasoning, problem solving, and social cognition.16 Although patients with affective psychoses may present with a similar pattern of deficits, the magnitude of the deficits in schizophrenia is substantially greater.17 A meta-analysis comparing cognitive deficits in patients with schizophrenia and bipolar disorder who had similar clinical and demographic characteristics demonstrated the impairments in schizophrenia to be, on average, 0.5 standard deviations greater than those in bipolar disorder.18 Importantly, cognitive performance in schizophrenia appears to be stable across fluctuations in illness symptoms, while deficits in affective disorders are more closely tied to clinical state.19,20 In a study of patients with psychosis, only those who had bipolar disorder had improvements in cognitive function with the resolution of the psychosis while those with schizophrenia performed at the same level cognitively regardless of changes in psychotic symptoms.19 Moreover, patients who go on to develop schizophrenia exhibit cognitive decline over the course of childhood and adolescence which occurs prior to the onset of psychotic symptoms.20 Conversely, those patients who go on to develop affective disorders do not demonstrate cognitive deficits until their affective symptoms have presented.21 Although social cognition is impaired in both schizophrenia and autism, the two disorders can be distinguished by relative preservation of basic social perceptual mechanisms in schizophrenia, wherein abnormalities are tied to deficits in higher order social cognitive processes.22 While cognitive deficits are widespread in neuropsychiatric disorders, the pattern and magnitude of these deficits in schizophrenia enables this disorder to be distinguished.

Cognitive deficits in schizophrenia are significantly correlated with functional outcome with regards to employment, independent living, community functioning, and social functioning.23-27 Indeed, the link between cognitive performance and functional outcome is substantially stronger than that between psychosis and functional outcome.23 While first generation antipsychotics can address the positive symptoms of schizophrenia, they appear to have modest, if any, effect on cognitive performance.28,29 There was initial hope based on preclinical data that second generation antipsychotics would be more effective in improving cognitive performance. Subsequent clinical studies, however, have not demonstrated any meaningful difference in their effect on cognition between the first and second generation antipsychotics.30,31

COGNITIVE DEFICITS AND NEUROPLASTICITY

The above observations underscore the identification of cognitive deficits as a core feature of schizophrenia and a key path toward understanding the etiopathology of this illness. In recent years, there has been increasing evidence that the core cognitive deficits in schizophrenia may stem from neurodevelopmentally-mediated alterations in brain plasticity.

Neural plasticity refers to the ability of neural circuits to alter their structure, function, and connectivity in response to experience. Over 50 years ago, Hebb32 postulated that synaptic plasticity is predicated on changes in synaptic efficacy, whereby repeated and persistent stimulation of the postsynaptic cell by the presynaptic cell increases the functional strength of the synapse connecting them. Experimental demonstration of this process, termed long-term potentiation (LTP), is accepted as a physiologic process underpinning learning and memory.33 Since the identification of LTP, numerous other mechanisms of plasticity have been identified, with complex interactions between the different forms of plasticity and the networks in which they operate. There is increasing evidence that this plasticity is central to understanding both normal and disordered neural functioning.34 While the exact mechanism of cognitive impairment in schizophrenia remains to be elucidated, disconnectivity within neural networks is gaining prominence as a theoretical model for functional impairment.35 It is thought that abnormal neuroplasticity underlies this disconnectivity and therefore plays a central role in the cognitive deficits of schizophrenia. Evidence for this altered plasticity is converging along multiple lines, including studies in neurophysiology, neuropharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36 For example, a study of neural plasticity using transcranial magnetic stimulation (TMS) demonstrated abnormal plasticity in both medicated and unmedicated patients with schizophrenia relative to healthy controls.37 Similarly, plasticity measured by electrophysiological responses to auditory conditioning is reduced in schizophrenia.38 Pharmacology, neuropathology, and genetics.36
logic agents, such as N-methyl D-aspartic acid (NMDA) antagonists, that can reproduce both the psychotic symptoms and cognitive deficits observed in schizophrenia have also been shown to affect neural plasticity. Genetic studies consistently implicate altered synaptic plasticity in the pathogenesis of schizophrenia, as many of the strongest candidate genes for schizophrenia influence the development and regulation of neural networks. Thus, it is increasingly believed that changes in neural plasticity may underlie the cognitive deficits and other clinical features of schizophrenia.

**NEUROPLASTICITY AS A THERAPEUTIC TARGET IN SCHIZOPHRENIA**

The significant personal and societal costs of schizophrenia highlight the importance of evidence-based interventions to reduce long-term morbidity. Unfortunately, to date, few successful efforts have been directed toward the treatment of cognitive deficits in schizophrenia, and clearly, alternate therapeutic targets are critically needed. In this context, the potential for employing the surviving functional neuroplasticity for therapeutic gain in schizophrenia and other neuropsychiatric disorders is of increasing importance.

Neuroplasticity is known to underlie functional recovery in a broad array of clinical conditions, including stroke, trauma, and spinal cord injuries. In a review of plasticity and training in animal models of the post-ischemic milieu, for example, Komitova et al. documented changes in cortical thickness, brain weight, gene expression, dendritic branching, and cortical mapping that were associated with an enriched environment. Exposure to enriched environments is analogous to learning through training with similar mechanisms at play in modifying brain function. Spontaneous clinical improvement in stroke, trauma, and spinal cord injuries is associated with observable changes at both the cellular level and within the functional connectivity of the relevant neural networks. Moreover, therapies designed to employ the brain’s plasticity have been shown to mimic or exceed these changes. For example, studies of post-stroke therapies demonstrate both restoration of functional organization and creation of neuronal projections while similar studies of brain or spinal cord injuries correlate clinical improvement with observable changes in functional and structural neuroimaging. There has been increasing interest in the possibility of involving neuroplasticity in the treatment of psychiatric disorders. Just as physical rehabilitation in the setting of trauma to the nervous system leads to functional improvement of the motor system, cognitive training is being developed across a variety of clinical conditions, from neurodevelopmental disorders to aging to neuropsychiatric illnesses, including schizophrenia. Such work has lead to the hypothesis that cognitive deficits in schizophrenia could be mitigated by treatment designed to improve the brain’s structural and functional integrity via neuroplasticity. Cognitive remediation approaches seek to address this goal; we discuss herein, using physical exercise as an analogy, the key principles underlying the application of neuroplasticity in developing these interventions.

**The More One Exercises, the Better**

Evidence for neuroplasticity and reshaping of neural networks that is both time-dependent and reliant upon repetitive training converges across a number of research modalities. Animal models demonstrate two distinct processes in the development of LTP. In the first phase, there is increased synaptic efficiency, such that an increased number of the signals that reach the presynaptic cell are passed on to the postsynaptic cell. This is mediated initially by post-synaptic glutamatergic NMDA receptors that detect coincident activity and induce both pre-synaptic and postsynaptic changes to increase efficiency. Alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors, via either increased insertion at the postsynaptic membrane or modification of their signaling properties, seem to be the mechanism by which this efficiency is induced. Analogous to the molecular mechanisms at play in LTP, human skill learning across multiple domains demonstrates rapid, but unsustainable, initial learning. Non-specific mechanisms, such as temporary changes in cortical representations, top-down organization related to task performance, and the increases in synaptic efficiency and neuronal excitability discussed above mediate the initial phase of performance improvement. Topographically, the rapid phase of learning is associated with activation and increased functional connectivity of regions involved in directed attention, such as the prefrontal cortex, anterior cingulate cortex, and posterior parietal cortex. These changes are not task-specific, but rather reflect generic heightened attention and effort resulting in activation of a set of regions known as the task-positive network. In contrast to these mechanisms, the second phase of LTP and learning is predicated upon synaptogenesis and reorganization of cortical representations. Late-phase...
LTP is associated with an increased number of functional synaptic sites between hippocampal neurons in the rat brain. Moreover, studies of rat hippocampal slices demonstrate that it is repetitive induction of late-phase LTP, rather than transitory excitation, that results in the generation of new synaptic structures. Given its slower time course and development with continued activity, synapticogenesis may contribute to the maintenance and stability of synaptic potentiation, thus underscoring the importance of sustained activity for achieving long-term functional changes. Whereas early phase learning is associated with activation of general attentional areas comprising the task-positive network, sustained learning is associated with regional activation with higher task specificity. That is, as a performance becomes more practiced, it is increasingly linked to activation of the specific neural systems that underpin it and decreasingly reliant on top-down attention. For example, the second phase of learned motor tasks results in increased activation of the motor areas of the brain, including the supplementary motor area, cingulate motor cortex, cerebellum, and basal ganglia, at the same time that decreased activation of the task-positive network is observed. In higher-order cognitive tasks, this reorganization may be represented not by increases in activity within a given region, but rather by increased functional connectivity in a distributed neural network. In order for neuroplasticity-mediated learning to result in durable functional changes, therefore, it is vital that the training be of sufficient duration to engage the second phase of learning. For example, a meta-analysis of cognitive remediation in schizophrenia, found that increased hours of remediation were associated with a larger effect size in verbal learning and verbal memory. Vinogradov et al. suggest that the relatively low intensity and brief duration of the studies of cognitive remediation to date may explain the fact that such meta-analyses have yet to document persistent, significant benefits to cognitive remediation. Future studies, therefore, will need to document the extent of treatment required to produce lasting results in order that adequate interventions be tested.

**Simple Exercise Should Precede Complex Tasks**

The second analogy to physical training is that it is better to start “bottom-up” with simple exercises, and gradually progress to more complex tasks.

Cognitive remediation approaches are likely to be more effective if simple cognitive processes are mastered before higher-level processes are addressed. Cognitive load theory formalizes this relationship, identifying increased ease of knowledge acquisition for information that builds upon existing knowledge relative to entirely novel information. The known information enables more efficient processing of information such that an increasing proportion of the cognitive load is devoted to learning and problem solving. A corollary to this statement is that impaired processing of simple information will undermine higher-order manipulation of this operation. Indeed, in schizophrenia patients, deficits in basic perceptual skills have been identified and shown to compromise performance of more complex cognitive operations. For example, impairments in a tone-matching task, in which subjects are asked to determine if two tones are identical or not, are linked to deficits in the ability to interpret another person’s emotions based on auditory information. Similarly, deficits in the processing of syllables are related to decreases in verbal learning and general cognition in both schizophrenia patients and healthy controls. Because deficits in simple perception necessitate an increased attentional load and recruitment of top-down operations to achieve basic processing, fewer top-down resources are available for higher-level cognitive operations.

Given this connection, there is increasing emphasis on the idea that training targeting basic sensory processes and simple cognitive functions will ultimately benefit higher-level cognitive operations. A study of aging adults demonstrated that training that produced improvement in early visual processing lead to improvements in working memory. Similar studies are beginning to emerge in schizophrenia research. For example, Adcock et al. have shown that an auditory training regimen can induce improvements in impaired sensory processing, such as the ability to distinguish two similar syllables. More importantly, they demonstrated that these basic improvements were associated with improvements in higher order functions, including linguistic processing, verbal cognition, and general cognition and that these changes were durable six months after training had concluded. Similarly, a social cognition training regimen that included practice in the basic skill of emotion perception was demonstrated to improve not only social cognition, but also social functioning in patients with schizophrenia, suggesting that the benefits generalize from test performance to actual functioning. Cognitive therapies, therefore, must both recognize and address the perceptual processing impairments that are present in schizophrenia if maximal improvements in higher order cognitive func-
tions are to be achieved.

**Personalized Exercises Work Better**

Finally, and again by analogy to physical exercise, interventions are most effective if they are tailored individually to each person’s capabilities and limitations. An important aspect of individual tailoring of one’s exercise regime is to monitor performance and gradually increase the difficulty; if too hard, one makes errors, and if too easy, the task gets boring. For maximal benefit therefore, it is important to have the tasks slightly above the threshold of challenge. Studies of learning and neuroplasticity conducted in the elderly demonstrate the importance of balancing attention, reward, and novelty in order to produce efficient learning. It is the balance of these features that lead to optimal engagement of the neuro-modulatory systems, including the acetylcholine, dopamine, norepinephrine, and serotonin signaling systems, which in turn modulate plasticity. The need to maintain this balance implies a need for training to increase in difficulty as increased learning occurs such that training remains at threshold. The importance of this principle is highlighted by a study of working memory training in patients with attention deficit hyperactivity disorder (ADHD) in which a training program with graded difficulty progression resulted in cognitive improvement while the same exercise organized in a non-progressive way did not lead to increased performance.

One of the learning approaches that has been observed to enhance learning is “errorless learning,” that is, intensive training at threshold. In contrast to conventional trial and error learning, which requires the learner to remember and incorporate feedback, errorless learning is based on repetitive exposure designed for the learner to succeed in a majority of trials, with difficulty gradually increasing as the learner develops mastery. Errorless learning takes advantage of implicit (learning without conscious awareness) learning processes that may be intact in schizophrenia; treatment induced improvements in implicit learning systems may thus help to restore impaired working memory and explicit memory processes. Errorless learning has been demonstrated to be effective in schizophrenia patients in both formal memory assessments and a study of work performance carried out in a community mental health center setting. Learning is also enhanced by personally salient stimuli. There is overwhelming evidence that emotionally-charged events enhance selective memory consolidation, perhaps mediated by the amygdale; emotionally-charged events are remembered better than emotionally neutral experiences, and emotion may enhance the subjective sense of recollection more than memory accuracy. Cognitive therapies that manage to personally engage the learner are thus more likely to produce meaningful and lasting improvement.

**COGNITIVE REMEDIATION APPROACHES**

Cognitive remediation is an intervention that seeks to enhance the neurocognitive skills in patients relevant to their recovery goals. Two distinct and complementary cognitive remediation approaches have been developed: the compensatory and the restorative approaches. Compensatory approaches utilize environmental supports and adaptive strategies to bypass cognitive deficits and improve target behaviors and functional outcomes in individuals with schizophrenia. In this paper, we focus on cognitive restoration approaches that seek to improve deficits in one or another cognitive function.

Wagner and Spaulding were among the first investigators to show that cognitive deficits in schizophrenia respond to remedial training. Several remediation approaches have since been developed, ranging from computer-based to paper and pencil and drill-and-practice to therapist-guided strategy coaching. These therapies rely on a range of basic cognitive processes, including perception, working memory, attention, and social cognition, along with combinations of these functions. In a meta-analysis of 26 studies, McGurk et al. found mean effect sizes of 0.41 for cognitive improvement and 0.36 for functional outcome. While effect sizes did not differ with regard to the type of remediation, a larger effect size in verbal memory was associated with more hours of remediation (0.57) compared with fewer hours (0.29). A more recent meta-analysis of 40 cognitive remediation studies conducted between 1973 and 2009 demonstrated a mean global cognition effect size of 0.45. Clearly, the effect sizes, though significant, were modest. Functional outcomes were significantly better in studies where cognitive remediation was combined with some other form of rehabilitation and when it included strategy coaching. Interventions are likely to be more successful when the skills trained closely approximate those needed in daily life. There is also evidence that patient variables such as levels of intrinsic and extrinsic motivation interact with treatment variables to produce a beneficial response to cognitive remediation. Going forward, better, multi-component strategies to enhance the therapeutic efficacy of
Cognitive remediation need to be identified. In designing effective cognitive remediation approaches, it is also important to adhere to the neuroscientific principles discussed earlier, i.e., an effective combination of drill and practice, "bottom-up" and "top-down" approaches, and personalized adaptation of training. Cognitive training approaches that are intrinsically motivating, used in a meaningful game-like context, those that personalize learning materials into themes of high interest value, and those that maximize patient control over the learning process are likely to be the most effective.93)

Cognitive enhancement therapy (CET) is a multi-component cognitive remediation approach, pioneered by the late Professor Gerard E. Hogarty in our group in Pittsburgh, that incorporates all of the above principles (cognitiveenhancementtherapy.com).94) CET is designed to provide enriched cognitive experiences through targeted and integrated neurocognitive and social-cognitive training. The focus is on enhancing both "bottom-up" processing of critical social stimuli, with "top-down" executive control over distracting information and emotional arousal. Through the integration of computer-based cognitive exercises in attention, training, and problem-solving, with an active social-cognitive group experience designed to facilitate perspective-taking, gistful processing of information, and social context appraisal, CET is thought to provide the requisite experiences needed to enhance neural processing and achieve adult cognitive milestones. The intervention involves weekly sessions for up to two years.

Evidence to date indicates that CET can successfully improve social and non-social cognitive impairments in schizophrenia. In a randomized-controlled study of 121 patients with chronic schizophrenia, Hogarty et al.95) demonstrated significant improvements in cognitive measures such as neurocognition, processing speed, and cognitive style in patients receiving CET relative to those undergoing enriched supportive therapy. This differential was evident in the first year of training and continued to increase throughout the two-year training period. Similarly, a study of CET in patients with early-course schizophrenia or schizoaffective disorder identified ongoing improvement in cognitive measures from year one to year two of treatment.96) While CET demonstrated only moderate beneficial effect size (d=0.46) in enhancing neurocognitive function, strong differential effects (d > 1.00) favoring CET on social cognition, cognitive style, and social adjustment composites were observed.94) These findings echoed a previous study demonstrating improvements in social cognition following CET in early course schizophrenia.95) Improvement in the employment rates and of patients in the CET cohort suggests that the benefits extend beyond formal testing to daily functioning.96) This functional improvement was mediated by neurocognitive gains, primarily in executive functioning, and social-cognitive gains in emotion management.95) Importantly, follow-up studies of each of these groups showed persistence in the functional benefits of CET at one-year post-treatment, suggesting that the therapy had engaged the learning mechanisms necessary for sustained change.96,97)

The therapeutic effects of CET may capitalize on brain plasticity processes to offer neuroprotection and improved brain function in the fronto-temporal areas implicated in cognitive impairment.52) Over the course of two years, schizophrenia patients receiving CET had greater preservation of gray matter volume in the left hippocampus, parahippocampal gyrus, and fusiform gyrus, and significantly greater gray matter increases in the left amygdala compared with those who received enriched supportive therapy.98) Gray matter preservation in the left parahippocampal and fusiform gyrus and greater gray matter increases in the left amygdala were significantly related to improved cognition.99) These structural changes are likely mediated by neuroplasticity in the relevant signaling networks and may be the mechanism by which the beneficial cognitive effects of CET occur. Interestingly, pre-treatment whole brain cortical surface area and gray matter volume ("cortical reserve") significantly moderated the effects of CET on social cognition, though not on neurocognition.99) Greater cortical reserve, particularly in the temporal cortex, predicted a rapid social-cognitive response to CET in the first year of treatment. Given the fact that patients with less neurobiological reserve achieved a comparable social-cognitive response by the second year, however, it is possible that the early response reflects the recruitment of "surplus" neural capacity, while later developing changes are due to the expansion or increased connectivity of the networks underlying these functions.99)

**FUTURE DIRECTIONS**

While cognitive remediation approaches are promising, many questions remain. Several future directions are on the horizon and are briefly outlined here.

**Synergy with Pharmacological Treatments**

It is important to examine how one can synergistically...
apply pharmacologic and psychosocial approaches. Pharmacological agents that may have a pro-cognitive benefit need to be developed and tested in combination with cognitive remediation. In recent years, psycho-pharmacological researchers have been increasingly drawn toward efforts to identify therapeutic agents that may address cognitive deficits in schizophrenia. The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative has sought to develop cognitive batteries that are sensitive to detect treatment effects, and the Treatment Units for Research on Neurocognition in Schizophrenia (TURNS) network has been spearheading efforts to test potential pro-cognitive compounds for efficacy. Several potential targets have been identified for enhancing cognition in schizophrenia, including dopaminergic, serotonergic, histaminergic, cholinergic, glutamatergic, γ-aminobutyric acid (GABA)ergic, adrenergic, and sigma receptors. For example, observations that individuals with schizophrenia smoke at a higher rate than the general population have led to the theory that these individuals may be attempting to “self-medicate” cognitive deficits associated with illness and/or antipsychotic treatment. Selective α7 and α4β2 nicotinic receptor agonists, have shown promising, but inconsistent, results in studies to date. Glutamatergic receptors, both ionotropic (NMDA, AMPA, and kainate-sensitive) and metabotropic (mGluR1-8) types, have been targeted for improving cognition. Because glycine modulates NMDA receptor function, the glycine agonist D-serine is under investigation and has shown positive preliminary results, while, inhibitors of glycine reuptake are also being studied. Studies of GABAergic agents, such as MK-0777-a GABA(A) α2/α3 partial agonist have produced conflicting results thus far. Modafinil and d-amphetamine have promising pro-cognitive effects, though their clinical use for this purpose in schizophrenia patients remains to be established. It is an intriguing, though thus far untested, possibility that may mediate some aspects of cognitive function in schizophrenia, such as catechol-o-methyl transferase, have been investigated as potential predictors of outcome with cognitive remediation, though with inconsistent results thus far. Genetic polymorphisms that may mediate some aspects of cognitive function in schizophrenia, such as catechol-o-methyl transferase, have been investigated as potential predictors of outcome with cognitive remediation, though with inconsistent results thus far. As research proceeds, therefore, appropriate pairing of patients with the cognitive remediation technique most likely to benefit them will maximize the likelihood of successful functional improvement.

Cognitive remediation is a promising approach to improve real-world functioning in patients with schizophrenia. Future studies must further elucidate the neural mechanisms underlying cognitive remediation and determine the optimal means by which to harness neuroplasticity. With regards to implementation, it will be important to develop cognitive remediation that can be delivered in community settings and to train front-line clinicians to do so. There is increasing evidence that cognitive remediation is most effective when combined with other psychosocial treatments, such as social skills training and supportive employment. Further work is needed to develop comprehensive approaches to cognitive remediation that incorporate key therapeutic principles from a variety of treatment modalities.

**Prediction and Personalization of Treatment**

Given how labor intensive such approaches are, it is essential to match patients with the specific cognitive remediation therapy to which they are most likely to respond. It is therefore critical to identify clinical, neurobiological, and genetic predictors of positive response to cognitive remediation interventions. For example, pre-treatment learning potential, the ability to attain and utilize cognitive skills after cognitive training, is a measure that has been shown to predict response to cognitive remediation. Other studies have highlighted motivation and the combination of sustained attention and working memory as the key predictors of response, with the latter two factors particularly associated with generalized functional improvement. Genetic polymorphisms that may mediate some aspects of cognitive function in schizophrenia, such as catechol-o-methyl transferase, have been investigated as potential predictors of outcome with cognitive remediation, though with inconsistent results thus far. As research proceeds, therefore, appropriate pairing of patients with the cognitive remediation technique most likely to benefit them will maximize the likelihood of successful functional improvement.

**Non-Invasive Stimulation Techniques**

Other, non-pharmacological, approaches to enhance neuroplasticity, such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), need to be considered as potential adjuncts to cognitive remediation. A recent study suggests that TMS applied to the prefrontal cortex may improve cognitive deficits in schizophrenia. Similarly, anodal tDCS, applied to the dorsolateral prefrontal cortex has been shown to improve cognitive functions including learning and memory in both healthy adults and in schizophrenia patients. Again, few studies have examined the potential synergistic effects of these approaches with cognitive remediation.
REFERENCES


35. Friston KJ. The disconnection hypothesis. Schizophr Res 1998;30:115-125.


75. Letman DJ, Foxe JJ, Butler PD, Saperstein A, Revheim N, Javitt DC. Sensory contributions to impaired prosodic processing in schizophrenia. Biol Psychiatry 2005;58:56-61.


